This month: Bovine/porcine FGF-2 out now, Qkine scale up manufacturing, why you should check vial recovery as part of your QC, and our latest blog article on our internship.
This month: download our latest poster on human pluripotent stem cell-directed differentiation, read a recent review article on human organoids and visit us in person at one of our upcoming events
This month: free growth factors for summer projects, GDNF, mLIF vs ESGRO and our new blog, the difference between growth factors and cytokines
This month: on-demand webinar, can R-spondin1 recombinant protein replace conditioned media? and enter our photo competition
this month: TGFbeta3 launched, photo competition now open and are endoderm implants the future of medicine?
Implantable endoderm organoids combine synthetic support structures and cells to repair or replace the function of endoderm-derived organs like the pancreas, liver, colon, stomach, intestines, lungs, and gall bladder. Adult cells are notoriously difficult to expand in vitro without loss of function, so many implants have harnessed new technologies based on induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). Pioneers in the field are working to optimize cell lines and effectively scale manufacture protocols to transition to the clinic and fulfill the promise of these next generation of stem cell therapies.
In this months pep talk we explore why quality isn't just about purity and a product spotlight on BMP-4 lot comparibility.
On Friday, 11th February, it’s International Day of Women and Girls in Science 2022. To celebrate, I’d like to give a big shout-out to people of all genders who champion gender equality in science and inspire the next generations of scientists, thank you!
Happy New Year! It’s five years since Marko and I founded Qkine, the time has flown. Highlights have been the wonderful feedback we’ve had from customers and launching innovative products such as the first true animal-free TGFβ1, tag-free thermostable FGF2-G3, and demonstrating the efficacy of HGF NK1 in hepatocyte differentiation.
There has been an impressive drive towards innovation in stem cell protocols this year. As 2021 comes to a close, we reflect on the highlights for stem cell science over the year. It was great to see new culture media, such as B8 and “Beefy-9”, published, developments in cultivated meat science hit the news and iPSC-based therapies edge closer to the clinic. Reproducibility remains the underlying theme, and indeed requirement, for maximising the impact of these wonderful developments and at Qkine we’ll continue to do everything we can to help in 2022.